Dengue Vaccine Dengvaxia: Who Qualifies & What Parents Need to Know

Is Your Child Ready for Dengue? The Parent’s Quick Check

Every summer in Delhi NCR, the buzz of mosquito nets and the fear of feverish children rise. As a parent in Gurgaon, Noida, or central Delhi, you’ve probably seen the headlines about dengue outbreaks and the promise of a vaccine that can stop the cycle. But the question remains: is Dengvaxia the right choice for my child? The answer isn’t as simple as a yes or no; it depends on your child’s age, past infection history, and local health guidelines. In this post, we’ll walk you through who qualifies for Dengvaxia, what the latest Indian Academy of Pediatrics (IAP) 2025 schedule says, and how you can protect your family with confidence.

Dengvaxia Explained: A Quick Overview

Dengvaxia (CYD-TDV) is a live attenuated tetravalent vaccine developed by Sanofi Pasteur. It targets all four dengue virus serotypes, aiming to reduce the severity of future infections. The World Health Organization (WHO) recommends it for children aged 9 to 45 years living in dengue‑endemic areas, but only after a confirmed prior dengue infection. This “serostatus‑dependent” approach is crucial because the vaccine can increase the risk of severe dengue in seronegative individuals.

In India, the Ministry of Health and Family Welfare has approved Dengvaxia for use in children aged 6 to 16 years in areas with a high dengue burden. The Indian Academy of Pediatrics (IAP) 2025 schedule lists Dengvaxia as a recommended vaccine for children who have had a laboratory‑confirmed dengue infection before the age of 16.

Who Qualifies for Dengvaxia? The Key Eligibility Criteria

• Age: 6–16 years (as per IAP 2025). The CDC and AAP also recommend the vaccine for this age group in endemic regions.
• Serostatus: Prior dengue infection confirmed by NS1 antigen, PCR, or IgG serology. The vaccine is contraindicated in seronegative children.
• Health Status: No severe immunosuppression, no active febrile illness at the time of vaccination, and no history of allergic reactions to vaccine components.
• Geographic Location: Residency in a dengue‑endemic zone—Delhi, Gurgaon, and Noida all fall into this category based on recent surveillance data.
• Consent: Written informed consent from the parent or guardian, with assent from older children.

To verify serostatus, your child’s pediatrician can order a simple blood test. If the result shows a previous dengue infection, you can move forward with the vaccination schedule.

How Dengvaxia Fits into the IAP 2025 Schedule

The IAP 2025 schedule places Dengvaxia as a recommended vaccine for children in the 6–16 age bracket who have had a documented dengue infection. The schedule also emphasizes a three‑dose series spaced 6–12 months apart. Below is a quick snapshot of the recommended timing:

• First dose: At 6–16 years, after confirming seropositivity.
• Second dose: 6 months after the first.
• Third dose: 12 months after the first (or 6 months after the second).

Unlike many routine vaccines, Dengvaxia’s schedule is tied to serostatus and local dengue incidence. Parents should coordinate closely with their child’s pediatrician and the local health department to ensure timely dosing.

Safety and Efficacy: What CDC, WHO, and AAP Say

The safety profile of Dengvaxia has been extensively studied in phase III trials across Asia, Latin America, and the Philippines. The key points from major health bodies are:

• WHO: Recommends Dengvaxia for seropositive individuals aged 9–45 in endemic settings. Emphasizes the need for pre‑vaccination serological testing.
• CDC: Supports use in seropositive children 9–16 years in high‑endemic areas, noting a modest reduction in hospitalization and severe dengue.
• AAP (American Academy of Pediatrics): Advises that the vaccine is safe for seropositive children but contraindicated for seronegatives. Calls for careful screening and monitoring.

In India, the Drug Controller General of India (DCGI) has approved Dengvaxia under a national immunisation program after reviewing WHO and CDC data. The vaccine’s adverse event profile is similar to other live vaccines: mild fever, injection site pain, and occasional rash—none of which are serious.

Practical Tips for Delhi Parents: From Testing to Home Vaccination

1. Get a Serology Test: Schedule a blood test with your child’s pediatrician. If your child has had dengue before, the test will confirm antibodies.

2. Plan the Three‑Dose Schedule: Mark the dates on your calendar. Use the Dengue Vaccine booking portal to set reminders.

3. Choose Home Vaccination: Avoid the hassle of clinic visits. Book a certified nurse visit at home by clicking here or calling 9999 109 040. Our GNM nurses, under doctor oversight, administer vaccines safely and offer post‑vaccination care.

4. Stay Informed About Local Outbreaks: Follow Delhi health bulletins and the Delhi Health Department’s updates. If an outbreak is reported, your child’s vaccination status becomes even more critical.

5. Review the Full Vaccine Catalogue: For parents interested in other vaccines, explore our View Full Vaccine Catalogue to keep your child’s immunisation record complete.

Common Misconceptions About Dengvaxia

• “If my child never had dengue, they can still get vaccinated.” False. The vaccine is only safe for seropositive children.
• “Dengvaxia is a one‑time shot.” Incorrect. It requires a three‑dose series spaced months apart.
• “The vaccine prevents dengue entirely.” Not entirely. It significantly reduces severe disease but does not guarantee 100% protection.

FAQ – What Parents Are Asking

1. Can a child who had dengue last year get Dengvaxia?

Yes. If the child had a laboratory‑confirmed dengue infection within the last 12 months, they are eligible. The vaccine is most effective when the child has had a prior infection.

2. Are there any long‑term side effects?

Clinical trials and post‑marketing surveillance show no serious long‑term adverse events. Mild reactions such as fever or soreness are common but resolve quickly.

3. How do I know if my child is seropositive?

Ask your pediatrician for an IgG serology test. The test will detect dengue antibodies indicating past infection.

4. Is Dengvaxia covered under the national immunisation programme?

It is available under the national programme in high‑endemic districts, but many families opt for private vaccination. Check with your local health authority for coverage details.

5. Can I get my child vaccinated at home?

Absolutely. Our certified GNM nurses can administer Dengvaxia at your doorstep. Book a home visit via our home vaccination booking link.

Take the First Step Today

Knowing the right information can transform your child’s health trajectory. If your child has had dengue and you’re in Delhi NCR, Dengvaxia offers a shield against severe disease. Don’t wait for an outbreak—schedule a serology test, confirm eligibility, and book your home vaccination visit today. Protect your child, protect your family, and keep the summer fever at bay.